Welcome to our dedicated page for Sinovac Biotech SEC filings (Ticker: SVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sinovac Biotech Ltd. (SVA) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer listed on Nasdaq. Sinovac furnishes information to the U.S. Securities and Exchange Commission (SEC) primarily through Form 20‑F annual reports and Form 6‑K current reports, which include press releases, proxy materials, and other significant updates.
For a vaccine-focused biopharmaceutical company like Sinovac, annual reports on Form 20‑F and related filings are central sources for understanding its vaccine portfolio, risk factors, and financial condition. While the specific contents of Sinovac’s 20‑F filings are not reproduced here, the company has publicly discussed delays in filing its 2024 annual report and its engagement of independent auditors to complete multi-year audits and internal control assessments. These filings are directly relevant for investors tracking compliance with Nasdaq Listing Rules and SEC reporting requirements.
Sinovac’s Form 6‑K submissions frequently attach press releases covering topics such as special shareholder meetings, litigation outcomes in Antigua and other jurisdictions, proxy advisory recommendations, dividend payments, and board communications. For example, recent 6‑Ks have furnished press releases on the adjournment of a Special Meeting of Shareholders, court decisions related to PIPE shares, the status of a US$55.00 per common share special cash dividend, and the engagement of new independent auditors.
Through this page, users can review Sinovac’s historical and recent 6‑K filings to follow governance disputes, corporate actions, and listing status updates, alongside financial reporting milestones. Stock Titan’s interface is designed to surface new filings as they are made available from EDGAR and to pair them with AI-powered summaries that explain the purpose of each document in plain language, such as distinguishing between a current report on Form 6‑K and an annual report on Form 20‑F.
Investors researching Sinovac’s regulatory history can use this filings archive to examine how the company has communicated about auditor changes, Nasdaq notifications regarding late filings and delisting determinations, proxy contests, and dividend distributions, all of which are documented in its SEC submissions.
SINOVAC BIOTECH LTD director and Chief Executive Officer Weidong Yin filed an initial insider ownership report. The filing shows he directly holds 6,359,500 common shares of the company’s stock. This Form 3 reflects his position as a reporting insider rather than a new transaction.
SINOVAC BIOTECH LTD director Andrew Y. Yan filed an initial ownership report on Form 3. The filing shows indirect ownership of 10,780,820 common shares held by SAIF Partners IV L.P., an investment entity for which he serves as the ultimate general partner.
The filing states he may be deemed to beneficially own the shares held by SAIF Partners IV L.P. but explicitly disclaims beneficial ownership except to the extent of his pecuniary interest. This report records existing holdings and does not reflect a new buy or sell transaction.
Sinovac Biotech Ltd. reported that its Board met on August 19, 2025 and refreshed several governance structures. The Board confirmed seven directors, including Andrew Yan and Simon Anderson, as independent under Nasdaq rules.
The Board appointed Simon Anderson and Yuk Lam Lo to the Audit Committee, with Anderson as chair, and amended the Audit Committee Charter to reduce the minimum size from three to two members, consistent with home-country practice for a foreign private issuer. It also named new members and chairs for the Compensation Committee and the Nominating and Governance Committee, and created a Litigation Committee of independent directors to evaluate claims in certain legal proceedings and make recommendations to the Board.
SINOVAC Biotech Ltd. has appointed UHY LLP, a U.S.-based member of the UHY International network, as its new independent auditor and registered public accounting firm, effective October 24, 2025.
UHY will audit SINOVAC’s financial statements for the years ended December 31, 2021, 2022, 2023, 2024 and 2025, including internal control audits as of December 31, 2024 and 2025, and conduct interim reviews for the six-month periods ended June 30, 2024 and 2025. The company plans to file Form 20-Fs and Form 6-Ks as soon as practicable to meet SEC and NASDAQ compliance requirements, which management links to its aim of trading resumption.
Sinovac Biotech Ltd. received a Nasdaq delisting determination on November 12, 2025 because it did not file its Form 20-F annual report for the year ended December 31, 2024 by the extended deadline of November 11, 2025. The delay followed the April 2025 resignation of its prior auditor, Grant Thornton Zhitong Certified Public Accountants LLP.
The company has engaged UHY LLP as its new independent auditor and is working to complete the audit and file the 2024 Annual Report. Sinovac plans to request a hearing before a Nasdaq Hearing Panel by November 19, 2025, which will trigger an automatic 15-day stay of any trading suspension, and it will seek a further stay while it pursues regaining compliance with Nasdaq Listing Rule 5250(c)(1).
Sinovac Biotech Ltd. filed a 6-K describing an Antigua High Court interim order that confirms the current group of eight directors, led by Chairman Andrew Y. Yan, will serve as the Company’s Board until a trial on a disputed July 2025 special shareholder meeting, scheduled for late April/early May 2026.
The Board reiterates its focus on shareholder value, completing the audit, supporting the CEO and management team, and working with advisors to resolve ongoing disputes. It also highlights efforts to restore trading of Sinovac’s shares on NASDAQ and maintain stable operations while advancing its vaccine portfolio and global partnerships.
Sinovac Biotech’s major shareholder SAIF Partners IV and its affiliated entities report continued beneficial ownership of 10,780,820 common shares, representing 15% of the company’s common shares, based on 71,860,702 shares outstanding as of March 31, 2024.
On December 15, 2025, SAIF Partners IV L.P. (the Seller) and YZ Healthcare L.P. (the Buyer) entered into an Amended and Restated Investment Agreement. The revisions extend the Buyer’s right of first refusal period for secondary sales by SAIF and limit the shares covered by that right to an amount equal in value to the Buyer’s deposit under the prior agreement. The amendment also extends the time during which SAIF may exercise a put option to sell designated shares to the Buyer, tied to whether a share purchase agreement is signed before the new right of first refusal period expires.
Sinovac Biotech Ltd. reports that Nasdaq has notified the company it is not in compliance with Listing Rule 5250(c)(2) because it failed to timely file a Form 6-K with interim financial statements for the second quarter of 2025.
Sinovac previously received a Nasdaq staff delisting determination in November 2025 and has appealed. A Nasdaq Hearings Panel will consider both the earlier delisting determination and this new late-filing issue at a hearing scheduled for January 8, 2026, where Sinovac plans to present a plan aimed at maintaining its Nasdaq listing.